c-Met-Targeted Antibody Therapy Pipeline Review

More info about license types

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: tbd
Format: PDF & Online Database
Product Line: Target Pipeline Review
Product Code: LMTP0156
Release Date: On the same day of purchase

c-Met-Targeted Antibody Therapy Pipeline Review

Target: c-Met (mesenchymal epithelial transition factor)

Product Category: Antibody; Radiopharmaceutical

This product provides basic information on antibody therapy candidates in research and development targeting c-Met.

This product consists of:

  • Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
  • Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
  • One-month online access to La Merie Publishing’s database for therapeutics and therapy candidates targeting c-Met (prerequisite: access to internet).

This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.

The c-MET signalling pathway consists of the mesenchymal epithelial transition factor (c-MET) transmembrane receptor tyrosine kinase receptor (RTK) and its ligand hepatocyte growth factor (HGF) or scatter factor (SF). Binding of HGF/SF to c-MET activates downstream signalling pathways such as Rho, focal adhesion kinase (FAK) and PI3K. These pathways regulate cancer cell growth, survival angiogenesis, invasion and metastasis. Thus, prevention of c-MET dependent neoplastic processes may provide a means for managing invasive tumors of high metastatic potential. c-Met is a well-characterized oncogene that is associated with poor prognosis in many solid tumor types.

In fact, c-MET/HGF has evolved as an attractive target for the pharmaceutical industry. Several c-Met RTK inhibitors have made it to the market to treat non-small cell lung cancer with specific MET mutations—Novartis’ Tabrecta (capmatinib), Merk KGaA’s Tepmetko (tepotinib) and AstraZeneca and HutchMed’s Orpathys (savolitinib) in China—validating c-Met as a viable target. While responses to c-Met RTK inhibitors have been observed in clinical trials, activity appears to be limited to those with MET gene amplifications or exon 14-skipping mutations, representing only small subsets of patients with tumors driven by signaling through the c-Met pathway, thereby necessitating selection of patients with MET amplification and/or c-Met activation most likely to respond.

As a cell surface receptor, c-Met is highly expressed in solid tumors, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), and, thus, may be well suited as a binding target for delivery of payloads.

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.


Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01